N-acetylcysteine for prevention of radiocontrast induced nephrotoxicity: the importance of dose and route of administration

Dose and route of administration of N-acetylcysteine are key factors to consider when evaluating whether this agent is effective in preventing radiocontrast induced nephropathy

[1]  A. Levin,et al.  A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. , 2004, American heart journal.

[2]  A. Colombo,et al.  Standard vs. double dose of N-acetylcysteine to prevent contrast agent associated nephrotoxicity , 2004 .

[3]  J. Sanderson,et al.  Effect of N-acetylcysteine for prevention of contrast nephropathy in patients with moderate to severe renal insufficiency: a randomized trial. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[4]  M. Tonelli,et al.  Systematic review of the impact of N-acetylcysteine on contrast nephropathy. , 2004, Kidney international.

[5]  C. Poole,et al.  N-acetylcysteine for the prevention of radiocontrast induced nephropathy: a meta-analysis of prospective controlled trials. , 2004, Journal of the American Society of Nephrology : JASN.

[6]  B. Krämer,et al.  The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. , 2004, Journal of the American Society of Nephrology : JASN.

[7]  M. Rudnick,et al.  N-acetylcysteine in the prevention of radiocontrast-induced nephropathy. , 2004, Journal of the American Society of Nephrology : JASN.

[8]  L. Borgström,et al.  Pharmacokinetics of N-acetylcysteine in man , 2004, European Journal of Clinical Pharmacology.

[9]  B. Jaber,et al.  Prevention of radiocontrast nephropathy with N-acetylcysteine in patients with chronic kidney disease: a meta-analysis of randomized, controlled trials. , 2004, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  P. O'Malley,et al.  Meta-analysis of randomized clinical trials on the usefulness of acetylcysteine for prevention of contrast nephropathy. , 2003, The American journal of cardiology.

[11]  J. Webb,et al.  Water for contrast-induced nephropathy? A thirst for knowledge. , 2003, The Journal of invasive cardiology.

[12]  F. Markowetz,et al.  Acetylcysteine for prevention of contrast nephropathy: meta-analysis , 2003, The Lancet.

[13]  A. Wragg,et al.  A rapid protocol for the prevention of contrast-induced renal dysfunction: the RAPPID study. , 2003, Journal of the American College of Cardiology.

[14]  Chi‐Hang Lee,et al.  Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention: a randomized controlled trial. , 2003, JAMA.

[15]  Y. Yazaki,et al.  Images in cardiology. , 2001, Heart.

[16]  W Zidek,et al.  Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. , 2000, The New England journal of medicine.